articleTop 1% cited
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Breast Cancer Research and Treatment · 2006 · Vol. 100(2) · pp. 229–235
Lisa M. McShane✉(National Cancer Institute)Douglas G. Altman(Cancer Research UK)Willi Sauerbrei(University Medical Center Freiburg)Sheila E. Taube(National Cancer Institute)Massimo Gion(Ospedale Civile Di Ivrea)Gary M. Clark
Radiomics and Machine Learning in Medical ImagingPancreatic and Hepatic Oncology ResearchMeta-analysis and systematic reviewsGeneralizability theoryMedicineBreast cancerCancerMEDLINETumor markerFamily medicineMedical physicsOncologyPsychology
MeSH terms
HumansNeoplasmsPrognosisResearch DesignBiomarkers, TumorGuidelines as TopicBiomedical Research
Funding
- National Cancer Institute
Citations
806
FWCI
16.99
field-weighted impact
References
48
Percentile
100%
vs. same field & year
Citations per year
Cited by
Assessing Bias in Studies of Prognostic Factors
Annals of Internal Medicine · 2013 · 3,036 citations
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
PLoS Medicine · 2012 · 1,021 citations
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
Breast Cancer Research and Treatment · 2013 · 342 citations
References
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
JAMA · 2000 · 20,480 citations
Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
JNCI Journal of the National Cancer Institute · 1994 · 1,124 citations
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
The Lancet · 2001 · 5,382 citations
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Annals of Internal Medicine · 2001 · 3,833 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.